QLT PhotoTherapeutics (QLTI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ian@SI who wrote (793)	1/9/2000 11:23:00 PM
From: Julian	Read Replies (1) of 1321

International Society for Optical Engineering Conference 3909 Saturday-Sunday 22-23 January 2000 San Jose, California Proceedings of SPIE Vol. 3909 [cut from: messages.yahoo.com ] Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy IX Conference Chair: Thomas J. Dougherty, Roswell Park Cancer Institute Saturday 22 January SESSION 1 Conv Ctr: Room A3 Sat. 8:30 am Clinical PDT Chair: Sandra O. Gollnick, Roswell Park Cancer Institute Please note that Thomas Dougherty from the Roswell Park Cancer Institute was the researcher responsible for the development of Photofrin and it would appear that a good portion of this conference's program deals with PDT/Photofrin in the treatment of malignacies with Dr. Julia Levy's supplementary presention on the use of PDT/Visudyne in AMD. It also appears as though QLT Phototherapeutics will come away from this with front-ranking recognition for its PDT treatment applications in both oncology and ophthalmology. spie.org

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next